Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Cost of Revenue (2024 - 2025)

Silence Therapeutics' Cost of Revenue history spans 2 years, with the latest figure at $12000.0 for Q4 2025.

  • For Q4 2025, Cost of Revenue fell 99.41% year-over-year to $12000.0; the TTM value through Dec 2025 reached $215000.0, down 98.18%, while the annual FY2025 figure was $215000.0, 98.18% down from the prior year.
  • Cost of Revenue for Q4 2025 was $12000.0 at Silence Therapeutics, down from $64000.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $3.6 million in Q3 2024 and bottomed at $12000.0 in Q4 2025.